Prof. Dr. Ziv J Haskal is a tenured professor at the University of Virginia School of Medicine.
His research has spanned the breadth of IR, beginning with defining early research in TIPS and complex portal hypertension: his preclinical experimental and human studies led to creation of the TIPS endograft used by majority of the planet. It included preclinical validation and in-human interventional trans-arterial gene vector delivery (one of the first human gene therapy trials); 1st demonstration of IR radiation eye injury risks at occupational levels; trials in pharmacomechanical DVT intervention; hemodialysis access care, including randomized trials of dialysis stent grafts that defined the first proven superior intervention for AV graft stenosis; liver transplant interventions; all aspects of embolization; and interventional oncology. He has published over 400 manuscripts, abstracts, chapters, books, letters, and editorials in journals such as the New England Journal of Medicine, Human Gene Therapy, Circulation, Hepatology, Radiology, CVIR, AJR, and JVIR. His papers have been cited >17000 times, His H-index exceeds 60. Prof. Haskal has led or participated in over 50 human/animal research studies.
Dr Haskal has given more than 700 invited lectures worldwide and been awarded numerous fellowships, national/ international awards for innovation, leadership, service, and research excellence. Prof. Haskal served as the Deputy Editor in Chief of CVIR. Thereafter he served two consecutive terms as the JVIR Editor in Chief (10 years) during which he nearly tripled its submissions, raised its Impact Factor to 3.037.